What does this research mean for the field?

Selective Internal Radiation Therapy (SIRT) provides favorable tumor response rates and improved quality of life for unresectable liver cancers, although its overall survival benefits compared to systemic therapy remain limited. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the clinical evidence, procedural principles, and technological advances of selective internal radiation therapy for managing unresectable hepatocellular malignancies.

September 5, 2026Indian Journal of Nuclear MedicineOpen Access

Selective Internal Radiation Therapy for Hepatocellular Malignancies: Existing Evidence and Advances

View Full Paper

Ask AI

Bookmark

Authors

PYPriyanka Yadav JSJaya Shukla

Discussion

Member takes

Overview

Narrative review reveals favorable tumor response but limited overall survival benefits for selective internal radiation therapy in unresectable liver cancer, highlighting the role of personalized...

Key Points

To review the clinical evidence, procedural principles, and technological advances of selective internal radiation therapy for managing unresectable hepatocellular malignancies.
Synthesized findings from pivotal clinical trials (SARAH, SIRveNIB, LEGACY, DOSISPHERE-01) investigating yttrium-90 radioembolization across diverse stages of hepatocellular carcinoma.
Evaluated technical innovations in artificial intelligence-assisted treatment planning, personalized dosimetry, post-therapy imaging, and alternative radioisotopes.
Demonstrated marked local tumor response rates and maintained patient quality of life across multiple clinical trials.
Found limited overall survival advantages when comparing intra-arterial radioembolization against standard systemic targeted therapies.
Identified personalized dosimetry and alternative radionuclides, such as holmium-166 and rhenium-188, as critical drivers for improving precision and worldwide affordability.

Cite This Study

Yadav et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4046b95aff0620eb57f https://doi.org/10.25259/ijnm_173_2026

View Full Paper

Ask AI

Bookmark

September 5, 2026Indian Journal of Nuclear MedicineOpen Access

Selective Internal Radiation Therapy for Hepatocellular Malignancies: Existing Evidence and Advances

View Full Paper

Ask AI

Bookmark

Authors

PYPriyanka Yadav JSJaya Shukla

Discussion

Member takes

Overview

Narrative review reveals favorable tumor response but limited overall survival benefits for selective internal radiation therapy in unresectable liver cancer, highlighting the role of personalized...

Key Points

To review the clinical evidence, procedural principles, and technological advances of selective internal radiation therapy for managing unresectable hepatocellular malignancies.
Synthesized findings from pivotal clinical trials (SARAH, SIRveNIB, LEGACY, DOSISPHERE-01) investigating yttrium-90 radioembolization across diverse stages of hepatocellular carcinoma.
Evaluated technical innovations in artificial intelligence-assisted treatment planning, personalized dosimetry, post-therapy imaging, and alternative radioisotopes.
Demonstrated marked local tumor response rates and maintained patient quality of life across multiple clinical trials.
Found limited overall survival advantages when comparing intra-arterial radioembolization against standard systemic targeted therapies.
Identified personalized dosimetry and alternative radionuclides, such as holmium-166 and rhenium-188, as critical drivers for improving precision and worldwide affordability.

Cite This Study

Yadav et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4046b95aff0620eb57f https://doi.org/10.25259/ijnm_173_2026

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark